First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial Angela Damato, Riziero Esposito Abate, Simona Tessitore, Daniela Frezzetti, Monica Rosaria Maiello, Dario Righelli, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Filippo Pietrantonio, Giuseppe Tonini, Tiziana Latiano, Roberto Bordonaro, Gerardo Rosati, Elisa Giommoni, Francesco Iachetta, Mario Larocca, Evaristo Maiello, Sara Lonardi, Alessandra Romagnani, Giuseppe Maglietta, Antonella De Luca, Nicola Normanno, Carmine Pinto Nature Communications, 2026 Immunotherapy achieved remarkable results in patients with deficient mismatch repair (dMMR)/microsatellite instable (MSI) metastatic colorectal carcinoma (mCRC). However, its efficacy in proficient MMR (pMMR)/microsatellite stable (MSS) mCRC remains limited. In the phase II NIVACOR trial, we evaluated the activity and safety of FOLFOXIRI/bevacizumab plus nivolumab as first-line therapy in patients with RAS/BRAF-mutated mCRC (NCT04072198). The primary endpoint of the trial was the Objective Response Rate (ORR) whereas secondary endpoints were safety profile, overall survival (OS), progression free survival (PFS), duration of response (DoR) and quality of life. The primary endpoint was met. Among the 73 enrolled patients, 76.7% achieved an objective response (95% CI, 65.4 to 85.8%), while the disease control rate was 97.3% (95% CI, 90.5 to 99.7%). The median progression-free survival (mPFS) was 10.1 months (95% CI, 9.0 to 14.3 months), and the median overall survival (mOS) was not reached. Treatment-related adverse events of grade 3 or higher occurred in 48 patients out 73 enrolled patients (65.8%). Comprehensive genomic profiling and RNA sequencing analysis revealed genomic and transcriptomic profiles associated with treatment response in pMMR/MSS patients. Alterations in pathways such as PI3K/AKT, chemokine signaling and DNA repair showed correlation with treatment activity. These findings highlight the potential synergy between immune checkpoint inhibitors and cytotoxic chemotherapy in selected patients with pMMR/MSS mCRC.
Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids Maria Latiano, Maria De Angelis, Anna Latiano, Orazio Palmieri, Tiziana Pia Latiano, Marco Donatello Delcuratolo, Matteo Tardio, Francesca Bazzocchi, Marco Gentile, Fulvia Terracciano, Grazia Anna Niro, Francesca Tavano Cells, 2026 Pancreatic cancer (PC) remains one of the most aggressive and lethal malignancies worldwide, largely due to late diagnosis, aggressive biology, limited therapeutic options and responsiveness. Conventional diagnostic and monitoring strategies, including imaging and serum biomarkers such as CA 19-9, provide limited sensitivity for early detection and suboptimal accuracy for the dynamic assessment of treatment response and disease evolution. These limitations highlight the urgent need for innovative, minimally invasive approaches capable of improving patient stratification and guiding personalized management. In this context, liquid biopsy has emerged as a promising, minimally invasive approach able to capture tumor-derived molecular information through the analysis of circulating cell-free nucleic acids, including circulating cell-free DNA (cfDNA) and circulating cell-free RNA (cfRNA). Released into the bloodstream by tumor cells, these analytes offer a real-time and comprehensive snapshot of tumor biology, capturing genetic, epigenetic, and transcriptional alterations through a simple blood draw. Liquid biopsy-based analyses hold significant potential for early detection, prognostic assessment, therapeutic decision-making, monitoring of minimal residual disease, and identification of resistance mechanisms. This review discusses the current state of research on circulating cell-free nucleic acids in PC, highlighting their biological basis, methodological approaches, clinical potential, and the challenges limiting their widespread implementation. By underscoring their translational relevance, we aim to outline how integrated liquid biopsy strategies, alongside the need for standardization and cross-study harmonization, may contribute to a more precise and dynamic approach to PC management.
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial D. Ciardiello, G. Martini, L. Boscolo Bielo, F. Pietrantonio, A. Raimondi, P. Manca, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A. Cogoni, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, T. Troiani, F. De Vita, E. Martinelli, F. Ciardiello, S. Napolitano, Davide Ciardiello, Giulia Martini, Luca Boscolo Bielo, Filippo Pietrantonio, Alessandra Raimondi, Paolo Manca, Salvatore Pisconti, Claudia Nisi, Giampaolo Tortora, Lisa Salvatore, Andrea Sartore-Bianchi, Salvatore Siena, Livio Blasi, Elena Ongaro, Alberto Zaniboni, Carmine Pinto, Lorenzo Antonuzzo, Antonio Avallone, Nicola Normanno, Giuseppe Santabarbara, Maria Giulia Zampino, Rossana Berardi, Alessio Cogoni, Claudio Lotesoriere, Tiziana Pia Latiano, Evaristo Maiello, Nicola Fazio, Giuseppe Curigliano, Roberto Bordonaro, Teresa Troiani, Ferdinando De Vita, Erika Martinelli, Fortunato Ciardiello, Stefania Napolitano, Marco Messina, Elisa Sperti, Fabio Fulfaro, Silvana Leo, Davide Melisi, Alessandro Pastorino, Emiliano Tamburini, Antonietta Fabbrocini, Laura Matteucci Annals of Oncology, 2026
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer V. De Falco, P.P. Vitiello, D. Ciardiello, G. Grasso, E. Mariella, G. Martini, S. Napolitano, C. Cardone, G. Arrichiello, E. Varriale, M. Di Bisceglie, T. Latiano, E. Maiello, A. Reginelli, M.C. Brunese, S. Cappabianca, S. Del Tufo, A. Orlando, A. Nicastro, F. Caraglia, L. Esposito, D. Renato, A. Avallone, M. Orditura, N. Fazio, G. Curigliano, M.G. Zampino, A. Bardelli, F. Ciardiello, T. Troiani, E. Martinelli ESMO Gastrointestinal Oncology, 2026 <h3>Background</h3> Angiogenesis is a key mechanism in metastatic colorectal cancer (mCRC). Novel agents targeting this pathway, like cabozantinib, are of great therapeutic need. <h3>Patients and methods</h3> We conducted an open-label, single-arm phase II trial to assess the antitumor activity of cabozantinib in patients with pretreated mCRC who had progressed following at least two prior lines of therapy. The primary endpoint was the progression-free survival (PFS) rate at 16 weeks, whereas secondary endpoints included median PFS, overall survival (OS), response rate, disease control rate, and safety. DNA- and RNA-based translational analyses were carried out on biological samples. <h3>Results</h3> From October 2019 to January 2023, 33 patients were treated with oral cabozantinib, 60 mg daily. The primary endpoint was met: 11/33 assessable patients (33%) were progression-free at 16 weeks. Median PFS was 2.27 months [95% confidence interval (CI) 1.71-3.65 months], median OS was 6.25 months (95% CI 3.81-10.26 months). Disease control rate was 45.5%. Cabozantinib was generally fairly tolerated. Exploratory analyses investigating the effect of clinical disease features on PFS showed no significant correlation. Comprehensive genomic profiling on 30 patients (tissues and plasma) suggested that absence of <i>TP53</i> mutations and tumor mutational burden (TMB) ≥4 mutations/Mb positively correlated with response (PFS >16 weeks). Additionally, for a subset of 18 (54.5%) patients, RNA sequencing from archival formalin-fixed paraffin-embedded samples was carried out. Molecular subtypes 4 (CMS4) was the most represented transcriptional subtype (10/18 cases). To verify if other transcriptional features were associated with treatment benefit, for each sample we computed gene set variation analysis. For epithelial-mesenchymal transition (EMT) and angiogenesis gene sets, we identified a trend toward higher scores in tumors from patients with longer PFS. <h3>Conclusion</h3> Within the limitations of a single-arm phase II trial, cabozantinib demonstrates both safety and antitumor activity in mCRC. The observed correlation between specific molecular features, such as EMT activation and angiogenesis, and cabozantinib activity is hypothesis-generating and warrants further investigation.
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study D. Ciardiello, L. Boscolo Bielo, S. Napolitano, E. Martinelli, T. Troiani, E. Cioli, T.P. Latiano, E. Maiello, P. Parente, A. Avallone, A. De Stefano, R. Bordonaro, A.E. Russo, C. Lotesoriere, S. Vallarelli, S. Pisconti, C. Nisi, E. Tamburini, M.G. Viola, S. Lonardi, C. Cremolini, D. Iacono, P. Tagliaferri, F. Pietrantonio, G. Tortora, G. Rosati, M.G. Zampino, G. Curigliano, A. Febbraro, N. Normanno, F. De Vita, N. Fazio, F. Ciardiello, G. Martini ESMO Gastrointestinal Oncology, 2026 Background: Human epidermal growth factor receptor 2 (HER-2) overexpression/amplification is a known prognostic and predictive biomarker in breast and gastric cancer.However, its role in metastatic colorectal cancer (mCRC) is still debated. Patients and methods:We conducted an exploratory analysis to investigate the role of HER-2 amplifications/ mutations in patients with RAS/BRAF V600 wild type (WT), microsatellite stable (MSS) mCRC enrolled in the CAPRI-2 GOIM trial, who received FOLFIRI/cetuximab as first-line therapy.At baseline, plasma and tumor tissue samples were collected for comprehensive genomic profiling using the FoundationOne CDx assay.HER-2 positive tumors were defined in case of HER-2 mutations or gene amplification, defined by using a gene copy number cut-off of 4.Results: Patients with HER-2 negative tumors had numerically higher objective response rates [78% versus 60%; oddratio, 1.95, 95% confidence interval (CI): 0.47-8; P = 0.4] compared with HER-2 positive tumors.Patients with HER-2 positive mCRC had worse median progression-free survival (PFS) [(7.54 months; 95% CI:4.99-Not evaluable (NE) versus 13.47 months (95% CI: 11.76-16.3);hazard ratio (HR): 2.47; 95% CI: 1.27-4.65;P = 0.007] as well as worse median overall survival [16.4 months (95% CI:9.4-NE) versus 33.4 (30.36-NE);HR: 2.54; 95% CI: 1.09-5.93;P = 0.031] compared with patients with HER-2 negative tumors.Of note, 6/7 cases with HER-2 mutations exhibited limited benefit from treatment with FOLFIRI plus cetuximab with PFS inferior to 8 months.Conclusion: Taken together, these results highlight the need to test HER-2 gene alterations for patients with RAS/ BRAF V600 WT, MSS mCRC, who are candidates for anti-epidermal growth factor receptor therapies.
Defining the role and competencies of the medical oncologist in diagnostic and therapeutic care pathways: Consensus recommendations from the Italian association of medical oncology (AIOM) Rossana Berardi, Francesca Rossi, Valentina Tarantino, Michele De Tursi, Angelo Dinota, Giancarlo Di Pinto, Roberto Bianco, Francesco Leonardi, Alessandra Bearz, Alessandra Fabi, Alessandro Pastorino, Franco Nolè, Paolo Alessandroni, Francesco Carrozza, Lucio Buffoni, Tiziana Latiano, Daniele Farci, Massimiliano Spada, Carmelo Bengala, Stefania Kinspergher, Marco Gunnellini, Antonella Brunello, Marcello Tucci, Filippo Pietrantonio, Ugo De Giorgi, Lorena Incorvaia, Giovanni Micallo, Antonio Russo, Rita Chiari, Matteo Lambertini, Giuseppe Curigliano, Saverio Cinieri, Nicola Silvestris, Francesco Perrone, Massimo Di Maio, Roberto Papa Journal of Cancer Policy, 2026 BACKGROUND: Diagnostic and Therapeutic Care Pathways (DTCPs) are clinical governance tools aimed at managing the care of specific patient populations through the coordinated application of standardized, evidence-based interventions by multidisciplinary teams. Their primary goal is to ensure equitable, timely, and cost-effective access to high-quality care. MATERIALS AND METHOD: A panel of recognized opinion leaders, endorsed by the Italian Association of Medical Oncology (AIOM), was convened to develop a consensus document defining the role of the medical oncologist within Multidisciplinary Oncology Groups (MOGs) and DTCPs. Employing the RAND/UCLA Appropriateness Method in its "consensus conference" format, the panel evaluated a series of statements derived from a review of the scientific literature and expert-generated Good Practice Points (GPPs). These statements addressed five key areas. To further support each topic, illustrative case studies were presented. RESULTS: A total of 21 articles met the inclusion criteria, yielding 88 evidence-based recommendations. Additionally, panel members contributed 9 further GPPs based on clinical expertise. Of the 97 total recommendations, 95 received a relevance score above 7, while 2 scored between 4 and 6.9; none scored below 4. CONCLUSIONS: This consensus effort and the resulting document represent a comprehensive evaluation of the available evidence regarding the role of medical oncologists within MOGs and DTCPs. The objective is to propose standardized criteria for the optimal management of cancer patients (pts) across all phases of care from initial diagnosis and staging to treatment, follow-up, and end-of-life support.
Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and Body–Tail Annacandida Villani, Gandino Mencarelli, Giovanna Cocomazzi, Elena Binda, Edy Virgili, Tiziana Pia Latiano, Evaristo Maiello, Viviana Contu, Francesco Perri, Concetta Panebianco, Valerio Pazienza Cancer Medicine, 2025 Background Pancreatic cancer (PC) remains one of the most lethal malignancies worldwide, characterized by late‐stage diagnosis and a poor prognosis. This study explores the clinical, biochemical, and gut microbiota differences between PC patients and healthy controls (CTRL), as well as between subgroups of PC patients with pancreatic head cancer (PHC) and pancreatic body‐tail cancer (PBTC). Methods A total of 72 PC patients and 37 CTRL subjects were included, with further stratification of PC patients into 45 PHC and 27 PBTC cases. Clinical and biochemical data were collected. Gut microbiota was analyzed by 16S rRNA gene sequencing. Alpha‐diversity indices, Firmicutes/Bacteroidetes ratio and taxonomic composition were evaluated and compared in all the experimental group. Correlation analyses were performed between specific bacterial taxa and biochemical markers and a Random Forest algorithm was applied to identify taxa discriminating PC from CTRL and PHC from PBTC. Results Clinical and biochemical data revealed significant heterogeneity between groups, with PHC patients exhibiting higher markers of inflammation and liver dysfunction, while PBTC patients showed relatively preserved physiological status. Gut microbiota analysis revealed significant dysbiosis in PC patients compared to CTRL. Alpha‐diversity indices demonstrated reduced species evenness in PC patients, while the Firmicutes/Bacteroidetes ratio was significantly lower. Taxonomic composition analysis indicated enrichment of pro‐inflammatory taxa and depletion of beneficial SCFA‐producing genera. However, subgroup comparisons revealed distinct microbial profiles, with PHC patients enriched in taxa associated with localized inflammation and PBTCs showing higher levels of anti‐inflammatory and SCFA‐producing bacteria. A correlation analysis linked specific bacteria to markers of liver dysfunction and systemic inflammation, such as GGT, ALP, and ESR, while SCFA‐producing taxa correlated negatively with inflammatory markers. A Random Forest algorithm identified key microbial taxa discriminating PC patients from CTRL and PHC from PBTC. Conclusions These findings highlight the interplay between microbiota composition, tumor localization, and systemic inflammation, showing a potential for microbiota‐based diagnostics and interventions in PC.
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy L. Boscolo Bielo, S. Napolitano, A. Avallone, F. Pietrantonio, R. Bordonaro, E. Maiello, S. Pisconti, E. Tamburini, C. Lotesoriere, G. Tortora, A. Zaniboni, L. Blasi, L. Antonuzzo, R. Berardi, P. Tagliaferri, C. Cremolini, S. Lonardi, C. Garufi, C. Pinto, E. Ongaro, G. Santabarbara, M. Scartozzi, V. De Falco, A. De Stefano, C. Cardone, A. Iacovucci, M.F. Bosco, A.E. Russo, T.P. Latiano, C. Nisi, M. Messina, N. Salmistraro, A. Sartore-Bianchi, S. Siena, M.G. Zampino, N. Fazio, N. Normanno, A. Febbraro, L.P. Guerrera, P. Parente, F. De Vita, E. Martinelli, T. Troiani, G. Curigliano, F. Ciardiello, G. Martini, D. Ciardiello ESMO Open, 2025 <h3>Background</h3> Translational studies have provided evidence that targeted therapies and chemotherapy might induce a status of adaptive mutability with an increase in the tumor mutational load. <h3>Patients and methods</h3> We conducted an analysis of pathogenic variants (PVs) detected by liquid biopsy (LBx)-based comprehensive genomic profiling in patients with chemo-refractory microsatellite-stable metastatic colorectal cancer (mCRC) pretreated with anti-epidermal growth factor receptor (EGFR) within the VELO and CAVE-2 GOIM studies compared with anti-EGFR naïve mCRC included in the CAPRI-2 GOIM trial. <h3>Results</h3> Overall, 559 patients with available samples for LBx analysis were included. EGFR pretreated tumors had significant enrichment for PVs in the MAPK signaling pathway with a median tumor mutational burden (TMB) [6 interquartile range (IQR 4-11) versus 4 (IQR 3-9), <i>P</i> < 0.0001]; 33.8% pretreated patients had TMB with ≥10 mutations per megabase compared with 9.7% patients before first-line anti-EGFR treatment. Higher mutational load correlated with <i>KRAS</i> (q = 0.07), <i>BRAF</i><sup>V600</sup> (q = 0.01), <i>ERBB2 AMP</i> (q = 0.06) and <i>EGFR ECD</i> (q = 0.07) PVs. Such association was not observed in patients naïve to anti-EGFR drugs. <i>MAPK</i> mutations were associated with higher TMB in anti-EGFR pretreated samples (beta = 4.0, <i>P</i> < 0.0001), but not in anti-EGFR-naïve samples (beta 1.2, <i>P</i> = 0.4). <h3>Conclusion</h3> These findings might support the investigation of immunotherapy in patients with mCRC pretreated with EGFR inhibitors with high mutational load.
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity? Riziero Esposito Abate, Alessandro Morabito, Michele Milella, Fabrizio Tabbò, Valentina Guarneri, Giacomo Pelizzari, Ilario G. Rapposelli, Rossana Berardi, Lucio Buffoni, Elisa Bennicelli, Francesca Zanelli, Carlo Tondini, Laura Attademo, Tiziana P. Latiano, Salvatore Corallo, Giancarlo Pruneri, Federica Marmorino, Orazio Caffo, Lorenzo Antonuzzo, Simona Tessitore, Silvia Novello, Giuseppe Curigliano, Carmine Pinto, Nicola Normanno, Antonella De Luca JCO Precision Oncology, 2025 PURPOSE Tumor comprehensive genomic profiling (CGP) may detect potential germline pathogenic/likely pathogenic (P/LP) alterations as secondary findings. We analyzed the frequency of potentially germline variants and large rearrangements (LRs) in the RATIONAL study, an Italian multicenter, observational clinical trial that collects next-generation sequencing–based tumor profiling data, and evaluated how these findings were managed by the enrolling centers. PATIENTS AND METHODS Patients prospectively enrolled in the pathway-B of the RATIONAL study and undergoing CGP with the FoundationOne CDx assays were included in the analysis. Potentially germline variants detected in 40 cancer susceptibility genes (CSGs) were classified in three classes with different actionability, most (MA), high (HA), and standard (SA), on the basis of penetrance, mutational spectrum, and intervention for prevention/early detection. RESULTS On the basis of the European Society of Medical Oncology recommendations, we identified 225 potentially germline P/LP variants in 193/1,339 (14.4%) enrolled patients. In particular, 62/225 (27.5%) variants were detected in genes classified as MA-CSG class, 53/225 (23.6%) in genes belonging to the HA-CSG class, and 110/225 (48.9%) in the SA-CSG class. In addition, we detected 58 LRs in the 16/40 CSGs in 53/1,339 (3.95%) patients. Information about germline-focused analysis and follow-up was available for 99 patients with potentially germline variants. Surprisingly, 95/99 (96%) patients were not referred to oncogenetic consultation and follow-up, including 30/32 (93.75%) patients with variants in the MA-CSG class. CONCLUSION Our data confirm the utility of CGP for the identification of potentially germline variants in CSGs, highlighting the importance of reporting LRs in addition to single-nucleotide variants and insertions/deletions. However, our findings also demonstrate a relative lack of knowledge of the implications of germline findings detected on tumor-only sequencing among oncologists and underline the need for specific training in this area.
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study Davide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, Eleonora Cioli, Tiziana Pia Latiano, Alfonso De Stefano, Emiliano Tamburini, Matteo Ramundo, Roberto Bordonaro, Alessia Erika Russo, Salvatore Pisconti, Claudia Nisi, Claudio Lotesoriere, Simona Vallarelli, Sara Lonardi, Viola Barruca, Chiara Cremolini, Giampaolo Tortora, Pierosandro Tagliaferri, Filippo Pietrantonio, Gerardo Rosati, Antonio Lucenti, Mario Scartozzi, Oronzo Brunetti, Maria Giulia Zampino, Alberto Zaniboni, Rossana Berardi, Giancarlo Paoletti, Antonio Febbraro, Erika Martinelli, Teresa Troiani, Nicola Normanno, Paola Parente, Nicola Fazio, Giuseppe Curigliano, Ferdinando De Vita, Antonio Avallone, Evaristo Maiello, Fortunato Ciardiello, Giulia Martini European Journal of Cancer, 2025
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) Alberto Puccini, Giuseppe Viscardi, Oriana Ciani, Fabio Efficace, Angela Piattelli, Giordano Domenico Beretta, Davide Petruzzelli, Patrizia Popoli, Francesco De Lorenzo, Francesco Longo, Marco Zibellini, Lara Gitto, Antonella Brunello, Evaristo Maiello, Alberto Servetto, Martina Pagliuca, Alessandra Raimondi, Laura Marandino, Saverio Cinieri, Elisabetta Iannelli, Carla Ida Ripamonti, Paolo Bossi, Gianmauro Numico, Tiziana Latiano, Carmine Pinto, Silvana Quaglini, Laura Locati, Gualberto Gussoni, Gianluca Mignone, Pricivel M Carrera, Ethan Basch, Massimo Di Maio, Francesco Perrone BMJ Oncology, 2025
Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper Umberto Malapelle, Valentina Angerilli, Rossana Intini, Francesca Bergamo, Chiara Cremolini, Federica Grillo, Elena Guerini Rocco, Tiziana Pia Latiano, Erika Martinelli, Nicola Normanno, Fabio Pagni, Paola Parente, Alessandro Pastorino, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Matteo Fassan Critical Reviews in Oncology Hematology, 2025
NRG/ErbB signaling: on the trail of a molecular fingerprint in mucinous carcinoma Domenico Trombetta, Federico Pio Fabrizio, Massimo Di Maio, Paola Parente, Laura Melocchi, Maurizio Martini, Angelo Sparaneo, Tiziana Pia Latiano, Paolo Graziano, Giulio Rossi, Lucia Anna Muscarella Expert Opinion on Therapeutic Targets, 2025
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial D. Ciardiello, L. Boscolo Bielo, S. Napolitano, E. Martinelli, T. Troiani, A. Nicastro, T.P. Latiano, P. Parente, E. Maiello, A. Avallone, N. Normanno, S. Pisconti, C. Nisi, R. Bordonaro, A.E. Russo, E. Tamburini, I. Toma, C. Lotesoriere, S. Vallarelli, M.G. Zampino, N. Fazio, G. Curigliano, F. De Vita, F. Ciardiello, G. Martini, Davide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, Erika Martinelli, Teresa Troiani, Antonella Nicastro, Tiziana Pia Latiano, Paola Parente, Evaristo Maiello, Antonio Avallone, Nicola Normanno, Salvatore Pisconti, Claudia Nisi, Roberto Bordonaro, Alessia Erika Russo, Emiliano Tamburrini, Ilaria Toma, Claudio Lotesoriere, Simona Vallarelli, Maria Giulia Zampino, Nicola Fazio, Giuseppe Curigliano, Fortunato Ciardiello, Giulia Martini, Sara Lonardi, Chiara Cremolini, Carlo Garufi, Pierosandro Tagliaferri, Giampaolo Tortora, Filippo Pietrantonio, Antonio Febbraro, Gerardo Rosati, Silvana Leo, Oronzo Brunetti, Rosanna Berardi, Saverio Cinieri, Mario Scartozzi, Alberto Zaniboni, Giancarlo Paoletti Annals of Oncology, 2024
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey M. Reni, E. Giommoni, F. Bergamo, L. Cavanna, F. Simionato, M. Spada, M. Di Marco, I. Bernardini, S.S. Cordio, T. Latiano, A. Spallanzani, N. Silvestris, G.G. Cardellino, M. Bonomi, M. Milella, G. Luchena, E. Tamburini, M. Macchini, G. Orsi, M. Modesti, L. Procaccio, A. Santoni, I. De Simone, L. Caldirola, F. Galli, C. Pinto Pancreatology, 2024
Downexpression of miR-200c-3p Contributes to Achalasia Disease by Targeting the PRKG1 Gene Lucia Micale, Carmela Fusco, Grazia Nardella, Orazio Palmieri, Tiziana Latiano, Domenica Gioffreda, Francesca Tavano, Anna Panza, Antonio Merla, Giuseppe Biscaglia, Marco Gentile, Antonello Cuttitta, Marco Castori, Francesco Perri, Anna Latiano International Journal of Molecular Sciences, 2023
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial Erika Martinelli, Giulia Martini, Vincenzo Famiglietti, Teresa Troiani, Stefania Napolitano, Filippo Pietrantonio, Davide Ciardiello, Marinella Terminiello, Carola Borrelli, Pietro Paolo Vitiello, Filippo De Braud, Federica Morano, Antonio Avallone, Nicola Normanno, Anna Nappi, Evaristo Maiello, Tiziana Latiano, Alfredo Falcone, Chiara Cremolini, Daniele Rossini, Giuseppe Santabarbara, Carmine Pinto, Daniele Santini, Claudia Cardone, Nicoletta Zanaletti, Alessandra Di Liello, Daniela Renato, Lucia Esposito, Francesca Marrone, Fortunato Ciardiello JAMA Oncology, 2021
Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation E. Grandone, G. Tiscia, R. Pesavento, Antonio De Laurenzo, D. Ceccato, M. Sartori, L. Mirabella, G. Cinnella, Mario Mastroianno, L. Dalfino, D. Colaizzo, R. Vettor, M. Intrieri, A. Ostuni, M. Margaglione, Paolo E. Annibale Filippo Giovanni Battista Cristiano Ma Alboini Antonioni Aucella Bochicchio Carbonelli Ca, P. E. Alboini, Annibale Antonioni, F. Aucella, G. Bochicchio, C. Carbonelli, M. Carella, M. Castori, A. Centonze, Gianluca Ciliberti, M. Copetti, M. Corritore, S. De Cosmo, L. D’Aloiso, M. D’Errico, Angela de Matthaeis, A. Del Gaudio, A. Di Giorgio, V. Giambra, A. Greco, L. Florio, A. Fontana, V. Inchingolo, M. Inglese, M. Labonia, Antonella La Marca, T. Latiano, M. Leone, E. Maiello, A. Mangia, Carmen Marciano, V. Massa, S. Massafra, Grazia Orciuli, N. Palladino, Rita Perna, P. Piscitelli, M. Piemontese, M. Prencipe, Pamela Raggi, M. Rodriquenz, Raffaele Russo, D. Sancarlo, A. Simeone, V. Trischitta, M. Zarrelli, Pasquale Vaira, Doriana Vergara, A. Vescovi Journal of Thrombosis and Thrombolysis, 2021
Correction to: Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation (Journal of Thrombosis and Thrombolysis, (2021), 52, 3, (772-778), 10.1007/s11239-021-02429-z) E. Grandone, G. Tiscia, R. Pesavento, Antonio De Laurenzo, D. Ceccato, M. Sartori, L. Mirabella, G. Cinnella, Mario Mastroianno, L. Dalfino, D. Colaizzo, R. Vettor, M. Intrieri, A. Ostuni, M. Margaglione, Paolo E. Annibale Filippo Giovanni Battista Cristiano Ma Alboini Antonioni Aucella Bochicchio Carbonelli Ca, P. E. Alboini, Annibale Antonioni, F. Aucella, G. Bochicchio, C. Carbonelli, M. Carella, M. Castori, A. Centonze, Gianluca Ciliberti, M. Copetti, M. Corritore, S. De Cosmo, L. D’Aloiso, M. D’Errico, Angela de Matthaeis, A. Del Gaudio, A. Di Giorgio, V. Giambra, A. Greco, L. Florio, A. Fontana, V. Inchingolo, M. Inglese, M. Labonia, Antonella La Marca, T. Latiano, M. Leone, E. Maiello, A. Mangia, Carmen Marciano, V. Massa, S. Massafra, G. Orciulo, N. Palladino, Rita Perna, P. Piscitelli, M. Piemontese, M. Prencipe, Pamela Raggi, M. Rodriquenz, Raffaele Russo, D. Sancarlo, A. Simeone, V. Trischitta, M. Zarrelli, Pasquale Vaira, Doriana Vergara, A. Vescovi Journal of Thrombosis and Thrombolysis, 2021
Italian results of the PRECONNECT study: Safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer Alberto Zaniboni, Carlo Antonio Barone, Maria Chiara Banzi, Francesca Bergamo, Livio Blasi, Roberto Bordonaro, Maria Di Bartolomeo, Francesco Di Costanzo, Giovanni Luca Frassineti, Carlo Garufi, Francesco Giuliani, Tiziana Pia Latiano, Erika Martinelli, Nicola Personeni, Patrizia Racca, Emiliano Tamburini, Giuseppe Tonini, Marie Georges Besse, Mario Spione, Alfredo Falcone Future Oncology, 2021
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer Davide Ciardiello, Giulia Martini, Vincenzo Famiglietti, Stefania Napolitano, Vincenzo De Falco, Teresa Troiani, Tiziana Pia Latiano, Javier Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Evaristo Maiello, Fortunato Ciardiello, Erika Martinelli Cancers, 2021
False-positive results of SARS-CoV-2 IgM/IgG antibody tests in sera stored before the 2020 pandemic in Italy Anna Latiano, Francesca Tavano, Anna Panza, Orazio Palmieri, Grazia A. Niro, Nicola Andriulli, Tiziana Latiano, Giuseppe Corritore, Domenica Gioffreda, Annamaria Gentile, Rosanna Fontana, Maria Guerra, Giuseppe Biscaglia, Fabrizio Bossa, Massimo Carella, Giuseppe Miscio, Lazzaro di Mauro International Journal of Infectious Diseases, 2021
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients Marzia Del Re, Saverio Cinieri, Angela Michelucci, Stefano Salvadori, Fotios Loupakis, Marta Schirripa, Chiara Cremolini, Stefania Crucitta, Cecilia Barbara, Angelo Di Leo, Tiziana Pia Latiano, Filippo Pietrantonio, Samantha Di Donato, Paolo Simi, Alessandro Passardi, Filippo De Braud, Giuseppe Altavilla, Claudio Zamagni, Roberto Bordonaro, Alfredo Butera, Evaristo Maiello, Carmine Pinto, Alfredo Falcone, Valentina Mazzotti, Riccardo Morganti, Romano Danesi Pharmacogenomics Journal, 2019
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer Gerardo Rosati, Raffaele Addeo, Giuseppe Aprile, Antonio Avallone, Domenico Bilancia, Silvia Brugnatelli, Gabriella Buccafusca, Chiara Carlomagno, Stefano Cordio, Sara Delfanti, Emanuela Dell’Aquila, Maurizio Di Bisceglie, Samantha Di Donato, Antonio Di Stasi, Domenico Germano, Francesco Giuliani, Cristina Granetto, Tiziana Pia Latiano, Silvana Leo, Paolo Tralongo, Maria Elena Stroppolo, Filippo Venturini, Salvatore Bianco Cancer Chemotherapy and Pharmacology, 2019
Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies Alberto Visioli, Fabrizio Giani, Nadia Trivieri, Riccardo Pracella, Elide Miccinilli, Maria Grazia Cariglia, Orazio Palumbo, Andrea Arleo, Fabio Dezi, Massimiliano Copetti, Laura Cajola, Silvia Restelli, Valerio Papa, Antonio Sciuto, Tiziana Pia Latiano, Massimo Carella, Dino Amadori, Giulia Gallerani, Riccardo Ricci, Sergio Alfieri, Graziano Pesole, Angelo L. Vescovi, Elena Binda Ebiomedicine, 2019
EphA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer Giulia Martini, Claudia Cardone, Pietro Paolo Vitiello, Valentina Belli, Stefania Napolitano, Teresa Troiani, Davide Ciardiello, Carminia Maria Della Corte, Floriana Morgillo, Nunzia Matrone, Vincenzo Sforza, Gianpaolo Papaccio, Vincenzo Desiderio, Mariel C. Paul, Veronica Moreno-Viedma, Nicola Normanno, Anna Maria Rachiglio, Virginia Tirino, Evaristo Maiello, Tiziana Pia Latiano, Daniele Rizzi, Giuseppe Signoriello, Maria Sibilia, Fortunato Ciardiello, Erika Martinelli Molecular Cancer Therapeutics, 2019
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, Angelica Petrillo, Rosa Berenato, Maria Maddalena Laterza, Filippo Pietrantonio, Federica Morano, Maria Antista, Sara Lonardi, Lorenzo Fornaro, Stefano Tamberi, Elisa Giommoni, Alberto Zaniboni, Lorenza Rimassa, Gianluca Tomasello, Teodoro Sava, Massimiliano Spada, Tiziana Latiano, Alessandro Bittoni, Alessandro Bertolini, Ilaria Proserpio, Katia Bruna Bencardino, Francesco Graziano, Giordano Beretta, Salvatore Galdy, Jole Ventriglia, Simone Scagnoli, Andrea Spallanzani, Raffaella Longarini, Ferdinando De Vita Targeted Oncology, 2018
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial E. Martinelli, C. Cardone, T. Troiani, N. Normanno, S. Pisconti, V. Sforza, A.R. Bordonaro, A.M. Rachiglio, M. Lambiase, T.P. Latiano, G. Modoni, S. Cordio, F. Giuliani, M. Biglietto, V. Montesarchio, C. Barone, G. Tonini, S. Cinieri, A. Febbraro, D. Rizzi, F. De Vita, M. Orditura, G. Colucci, E. Maiello, F. Ciardiello, Vincenzo Iaffaioli, Guglielmo Nasti, Anna Nappi, Gerardo Botti, F. Tatangelo, Nicoletta Chicchinelli, Mirko Montrone, Annamaria Sebastio, Tiziana Guarino, Gianni Simone, Paolo Graziano, Cinzia Chiarazzo, GabrieleDi Maggio, Laura Longhitano, Mario Manusia, Giacomo Cartenì, Oscar Nappi, Pietro Micheli, Luigi Leo, Sabrina Rossi, Alessandra Cassano, Eugenio Tommaselli, Guido Giordano, Francesco Sponziello, Antonella Marino, Antonio Rinaldi, Sante Romito, Andrea Onetti Muda, Vito Lorusso, Silvana Leo, Sandro Barni, Giuseppe Grimaldi, Michele Aieta ESMO Open, 2017
Crohn's disease localization displays different predisposing genetic variants Orazio Palmieri, Fabrizio Bossa, Maria Rosa Valvano, Giuseppe Corritore, Tiziana Latiano, Giuseppina Martino, Renata D’Incà, Salvatore Cucchiara, Maria Pastore, Mario D’Altilia, Daniela Scimeca, Giuseppe Biscaglia, Angelo Andriulli, Anna Latiano Plos One, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial E. Martinelli, C. Cardone, T. Troiani, N. Normanno, S. Pisconti, V. Sforza, A.R. Bordonaro, A.M. Rachiglio, M. Lambiase, T.P. Latiano, G. Modoni, S. Cordio, F. Giuliani, M. Biglietto, V. Montesarchio, C. Barone, G. Tonini, S. Cinieri, A. Febbraro, D. Rizzi, F. De Vita, M. Orditura, G. Colucci, E. Maiello, F. Ciardiello, Vincenzo Iaffaioli, Guglielmo Nasti, Anna Nappi, Gerardo Botti, F. Tatangelo, Nicoletta Chicchinelli, Mirko Montrone, Annamaria Sebastio, Tiziana Guarino, Gianni Simone, Paolo Graziano, Cinzia Chiarazzo, GabrieleDi Maggio, Laura Longhitano, Mario Manusia, Giacomo Cartenì, Oscar Nappi, Pietro Micheli, Luigi Leo, Sabrina Rossi, Alessandra Cassano, Eugenio Tommaselli, Guido Giordano, Francesco Sponziello, Antonella Marino, Antonio Rinaldi, Sante Romito, Andrea Onetti Muda, Vito Lorusso, Silvana Leo, Sandro Barni, Giuseppe Grimaldi, Michele Aieta ESMO Open, 2016
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX F. Ciardiello, N. Normanno, E. Martinelli, T. Troiani, S. Pisconti, C. Cardone, A. Nappi, A.R. Bordonaro, M. Rachiglio, M. Lambiase, T.P. Latiano, G. Modoni, S. Cordio, F. Giuliani, M. Biglietto, V. Montesarchio, C. Barone, G. Tonini, S. Cinieri, A. Febbraro, D. Rizzi, F. De Vita, M. Orditura, G. Colucci, E. Maiello, Vincenzo Iaffaioli, Guglielmo Nasti, Gerardo Botti, F. Tatangelo, Nicoletta Chicchinelli, Mirko Montrone, Annamaria Sebastio, Tiziana Guarino, Gianni Simone, Paolo Graziano, Cinzia Chiarazzo, Gabriele Di Maggio, Laura Longhitano, Mario Manusia, Giacomo Cartenì, Oscar Nappi, Pietro Micheli, Luigi Leo, Sabrina Rossi, Alessandra Cassano, Eugenio Tommaselli, Guido Giordano, Francesco Sponziello, Antonella Marino, Antonio Rinaldi, Sante Romito, Andrea Onetti Muda, Vito Lorusso, Silvana Leo, Sandro Barni, Giuseppe Grimaldi, Michele Aieta Annals of Oncology, 2016
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial N. Normanno, A.M. Rachiglio, M. Lambiase, E. Martinelli, F. Fenizia, C. Esposito, C. Roma, T. Troiani, D. Rizzi, F. Tatangelo, G. Botti, E. Maiello, G. Colucci, F. Ciardiello, F. Giuliani, G. Simone, A. Febbraro, E. Tommaselli, S. Cinieri, M. Criscuolo, A. Perrino, A. Rinaldi, R. Bordonaro, M. Manusia, S. Romito, P. Bufo, G. Cartenì, M. Biglietto, O. Nappi, A. Cardarelli, E. Montesarchio, P. Micheli, G. Nasti, N. Chicchinelli, A. Iannaccone, A. Russo, D. Cabibi, P. Giaccone, C. Barone, G. Rindi, G. Tonini, A. Onetti Muda, G. Perrone, T. Latiano, P. Graziano, S. Pisconti, A. Sebastio Annals of Oncology, 2015
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study Lorenzo Antonuzzo, Elisa Giommoni, Davide Pastorelli, Tiziana Latiano, Ida Pavese, Domenico Azzarello, Michele Aieta, Ilaria Pastina, Francesca Di Fabio, Alessandro Bertolini, Domenico Cristiano Corsi, Selene Mogavero, Valentina Angelini, Mario Pazzagli, Francesco Di Costanzo World Journal of Gastroenterology, 2015
Combined modality treatments in pancreatic cancer Lucia Lombardi, Michele Troiano, Nicola Silvestris, Luciano Nanni, Tiziana Pia Latiano, Gabriele Di Maggio, Saverio Cinieri, Pierluigi Di Sebastiano, Giuseppe Colucci, Evaristo Maiello Expert Opinion on Therapeutic Targets, 2012
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study D. Santini, M. Tampellini, B. Vincenzi, T. Ibrahim, C. Ortega, V. Virzi, N. Silvestris, R. Berardi, C. Masini, N. Calipari, D. Ottaviani, V. Catalano, G. Badalamenti, R. Giannicola, F. Fabbri, O. Venditti, M.E. Fratto, C. Mazzara, T.P. Latiano, F. Bertolini, F. Petrelli, A. Ottone, C. Caroti, L. Salvatore, A. Falcone, P. Giordani, R. Addeo, M. Aglietta, S. Cascinu, S. Barni, E. Maiello, G. Tonini Annals of Oncology, 2012
